Visual Breakdown of Psychological Research-Related Federal Funding

This chart presents the breakdown of federal funding for psychological research, by field, in billions of dollars. The data was collected in 2016 by the American Psychological Association. The breakdown shows clearly the disparity between funding for computer sciences and mathematics as compared to fields like the social sciences and psychology. With efforts being made to raise awareness around psychedelic research, an increased focus on the field of psychology may be in store. With phase III testing already underway for MDMA, which has been granted “breakthrough status” by the FDA for testing on PTSD-patients, such testing is in the planning stages for psilocybin. If phase III testing yields conclusive findings and psilocybin is rescheduled, researchers like President of the Heffter Research Institute, George Greer, say they hope government funding for psychological research – specifically psychedelic research – becomes a reality.

This chart offers the percent breakdown of psychological research funding, by type of federal agency. The 2014 data collected by the American PsychologicalAssociation distinguishes the National Institutes of Health as the largest percent recipients of psychological research funding, across all other major federal agencies. Being a major influencing sector, the National Institutes of Health house many subsectors, including the National Insitute of Mental Health. 

 

 

This chart shows the actual versus estimated funding breakdown, by research type and disease area, in millions of dollars. The data collected by the National Institutes of Health are from the years 2016-2018. Pertinent to this story, is the $5,589 million dollars that go towards cancer research, as compared to just $410 million to depression and $174 million to anxiety disorders.

 

This chart shows the estimated medical and health research expenditure breakdown, by industry, in millions of dollars. The data collected was from 2015, by Research America. It is specific to the United States. What is important to note here is the huge disparity in estimated expenditures within the pharmaceutical industry, as compared to medical technology, biotechnology and other sectors.